{"disease":{"id":"immune-complex-membranoproliferative-glomerulonephritis","name":"immune complex membranoproliferative glomerulonephritis"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03955445","title":"Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":225,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05067127","title":"Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":124,"lead_sponsor_name":"Apellis Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT03459443","title":"A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":22,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT03723512","title":"Non-contrast Enhanced MRI in Patients With C3 Glomerulopathy (C3G) or Immune-complex Membranoproliferative Glomerulonephritis (IC-MPGN) Enrolled in the ACH471-205 Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":7,"lead_sponsor_name":"Mario Negri Institute for Pharmacological Research","has_results":false},{"nct_id":"NCT03124368","title":"A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":6,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT04729062","title":"C3G/Primary IC-MPGN EAP","phase":"","overall_status":"APPROVED_FOR_MARKETING","enrollment_count":null,"lead_sponsor_name":"Apellis Pharmaceuticals, Inc.","has_results":false}],"total":6},"guidelines":[],"source":"Drug Landscape verified database"}